within Pharmacolibrary.Drugs.ATC.N;

model N05BA56
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 1.8333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05BA56</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lorazepam, in combination products, is a benzodiazepine used for its anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant properties. It is prescribed primarily for the treatment of anxiety disorders, insomnia, premedication for anesthesia, and acute management of seizures. As a combination, it may be used with other agents for synergistic effects. It is an approved and widely used drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult, healthy individuals receiving lorazepam in combination formulations.</p><h4>References</h4><ol><li><p>Uthman, BM, et al., &amp; Ramsay, RE (1996). Intramuscular use of fosphenytoin: an overview. <i>Neurology</i> 46(6 Suppl 1) S24–S28. DOI:<a href=&quot;https://doi.org/10.1212/wnl.46.6_suppl_1.24s&quot;>10.1212/wnl.46.6_suppl_1.24s</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8649611/&quot;>https://pubmed.ncbi.nlm.nih.gov/8649611</a></p></li><li><p>Cañas, F, et al., &amp; Montes, JM (2011). Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder. <i>Expert opinion on pharmacotherapy</i> 12(14) 2245–2263. DOI:<a href=&quot;https://doi.org/10.1517/14656566.2011.605787&quot;>10.1517/14656566.2011.605787</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21801083/&quot;>https://pubmed.ncbi.nlm.nih.gov/21801083</a></p></li><li><p>Schachter, M, et al., &amp; Söhlke, E (1998). Safety and tolerability of moxonidine in the treatment of hypertension. <i>Drug safety</i> 19(3) 191–203. DOI:<a href=&quot;https://doi.org/10.2165/00002018-199819030-00003&quot;>10.2165/00002018-199819030-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9747666/&quot;>https://pubmed.ncbi.nlm.nih.gov/9747666</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05BA56;
